Heterosubtypic immunity to H7N9 influenza virus in isogenic guinea pigs after infection with pandemic H1N1 virus

Wiersma, Lidewij; Trierum, Stella E. Vogelzang-van; Kreijtz, Joost H. C. M.; Amerongen, Geert van; Run, Peter van; Ladwig, Mechtild; Banneke, Stefanie; Schaefer, Hubert; Fouchier, Ron A. M.; Kuiken, Thijs; Osterhaus, Albert D. M. E.; Rimmelzwaan, Guus F.

doi:10.1016/j.vaccine.2015.08.038

Cited by 4 publications

(1 citation statement)

References 38 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When mice that have recovered from a primary influenza infection are re-infected with a heterologous IAV (a strain with different surface glycoproteins but the same internal proteins) that is resistant to neutralization by antibody induced by the primary infection, influenzaspecific CD8 + T cells are responsible for accelerated viral clearance and reduced disease burden [13,[59][60][61]. Studies in guinea pigs also demonstrated that priming with the 2009 pandemic H1N1 virus confers protection against the 2013 avian H7N9 IAV [62]. Recently influenzaspecific tissue-resident memory (TRM) CD8 + T cells in the upper respiratory tract of mice were shown to be important in mediating protection from pulmonary influenza virus infection [63].…”

Section: Cd8 + T Cells Confer Cross-protection Across Different Influmentioning

confidence: 99%

Innate and adaptive T cells in influenza disease

et al. 2018

View full text Add to dashboard Cite

Influenza is a major global health problem, causing infections of the respiratory tract, often leading to acute pneumonia, life-threatening complications and even deaths. Over the last seven decades, vaccination strategies have been utilized to protect people from complications of influenza, especially groups at high risk of severe disease. While current vaccination regimens elicit strain-specific antibody responses, they fail to generate cross-protection against seasonal, pandemic and avian viruses. Moreover, vaccines designed to generate influenza-specific T-cell responses are yet to be optimized. During natural infection, viral replication is initially controlled by innate immunity before adaptive immune responses (T cells and antibody-producing B cells) achieve viral clearance and host recovery. Adaptive T and B cells maintain immunological memory and provide protection against subsequent infections with related influenza viruses. Recent studies also shed light on the role of innate T-cells (MAIT cells, γδ cells, and NKT cells) in controlling influenza and linking innate and adaptive immune mechanisms, thus making them attractive targets for vaccination strategies. We summarize the current knowledge on influenza-specific innate MAIT and γδ T cells as well as adaptive CD8 and CD4 T cells, and discuss how these responses can be harnessed by novel vaccine strategies to elicit cross-protective immunity against different influenza strains and subtypes.

show abstract